Research map: Tislelizumab combined with Anti-GD2 antibody-based chemoimmunotherapy for pediatric relapsed/refractory high-risk neuroblastoma: a two-Case Report

Back to the article

Papers in this map

  1. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy · Suzanne Louise Topalian · 2015 · 4353 citations · Cited by this paper
  2. Linalool in cancer pharmacology: pharmacokinetic limitations and preclinical cytotoxic evidence for translational development · 2026 · Related
  3. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study · Gemma Gatta · 2013 · 1100 citations · Cited by this paper
  4. A nomogram based on LASSO-logistic regression for predicting tocilizumab-associated hypofibrinogenemia in patients with rheumatic diseases · 2026 · Related
  5. Advances in Risk Classification and Treatment Strategies for Neuroblastoma · Navin R. Pinto · 2015 · 947 citations · Cited by this paper
  6. Traditional Chinese medicine interventions targeting Wnt/β-catenin signaling in cerebral ischemia/reperfusion injury: a review · 2026 · Related
  7. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial · Birgit Geoerger · 2019 · 358 citations · Cited by this paper
  8. NSFC-funded Chinese materia medica research (2015–2024): achievements output, research characteristics, and evolution · 2026 · Related
  9. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study · Jianming Xu · 2023 · 341 citations · Cited by this paper
  10. Endothelial EPAS1 as a prognostic and therapeutic target in acute myocardial infarction: integrative bioinformatics, Mendelian randomization and experimental validation · 2026 · Related
  11. Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross-sectional study · Xin Ni · 2022 · 245 citations · Cited by this paper
  12. Hematopoietic and T-lymphopoiesis-stimulating effects of a fluorinated pyrazolopiperidine β-cyclodextrin complex in cyclophosphamide-induced hematopoietic suppression · 2026 · Related
  13. Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1) · Ruth Lydia Ladenstein · 2020 · 152 citations · Cited by this paper
  14. Ganhai Weikang Capsules ameliorate functional dyspepsia in rats by modulating gut microbiota and host metabolic homeostasis · 2026 · Related
  15. PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance · Alessandra Dondero · 2015 · 119 citations · Cited by this paper
  16. Therapeutic potential of traditional Chinese medicine for hyperuricemia: mechanistic insights and clinical prospects · 2026 · Related
  17. Global, regional, and national epidemiology of childhood neuroblastoma (1990–2021): a statistical analysis of incidence, mortality, and DALYs · Jusen Nong · 2024 · 84 citations · Cited by this paper
  18. Exercise-induced myokine irisin protects against obesity-associated ischemic stroke via integrin αVβ5 signaling · 2026 · Related
  19. TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells · Marianne L. Boes · 2015 · 76 citations · Cited by this paper
  20. Therapeutic effect of Yupingfeng powder and its bioactive metabolites on renal diseases · 2026 · Related
  21. PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD 2 antibody ch14.18/CHO · Nikolai Siebert · 2017 · 70 citations · Cited by this paper
  22. Biology of GD2 ganglioside: implications for cancer immunotherapy · Pierre Machy · 2023 · 60 citations · Cited by this paper
  23. Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology · Rochelle Bagatell · 2024 · 58 citations · Cited by this paper
  24. Treatment and outcomes of 1041 pediatric patients with neuroblastoma who received multidisciplinary care in China · Yan Su · 2020 · 46 citations · Cited by this paper
  25. Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor · Benjamin Joshua Lerman · 2022 · 46 citations · Cited by this paper
  26. The role of programmed cell death‐1 (PD‐1) and its ligands in pediatric cancer · Laura S. van Dam · 2014 · 34 citations · Cited by this paper
  27. Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes · Juan Pablo Muñoz · 2023 · 27 citations · Cited by this paper
  28. Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report · Jaume Mora · 2023 · 24 citations · Cited by this paper
  29. Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta · Nikolai Siebert · 2023 · 18 citations · Cited by this paper
  30. Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study · Yi Que · 2023 · 16 citations · Cited by this paper
  31. Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma · Chenkai Mao · 2024 · 15 citations · Cited by this paper
  32. Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial · Juliet C. Gray · 2025 · 11 citations · Cited by this paper
  33. Assessment of Chemo-Immunotherapy Regimens in Patients with Refractory or Relapsed Neuroblastoma: A Systematic Review with Meta-Analysis of Critical Oncological Outcomes · Nur Olgun · 2025 · 7 citations · Cited by this paper
  34. Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma: Data from the Hungarian Pediatric Oncology Network · Márk Hernádfői · 2025 · 5 citations · Cited by this paper
  35. A 2035 Clinical Research Vision and Roadmap for High‐Risk Neuroblastoma · Lucas Moreno · 2025 · 3 citations · Cited by this paper
  36. Single-Center Cohort of Pediatric Patients with High-Risk Neuroblastoma Receiving Immunotherapy · Emese Zsigrai · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)